VPF
ONCY

Vantage Point Financial’s Oncolytics Biotech ONCY Stock Holding History

Vantage Point Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2K Hold
29,744
– – 0.01% 176
2025
Q4 		$26K Hold
29,744
– – 0.01% 169
2025
Q3 		$41.6K Hold
29,744
– – 0.02% 155
2025
Q2 		$23K Hold
29,744
– – 0.01% 148
2025
Q1 		$16.4K Hold
29,744
– – 0.01% 131
2024
Q4 		$27.2K Buy
+29,744
New +$31K 0.01% 122

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Vantage Point Financial's ONCY Position: Q1 2026 in Review

Vantage Point Financial held its Oncolytics Biotech (ONCY) position steady in Q1 2026 at 29,744 shares worth $25.2K. The position accounts for 0.01% of the portfolio, ranked #176.

Vantage Point Financial first reported a position in ONCY in Q4 2024 and has held it in 6 quarters since. The position peaked at $41.6K in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Vantage Point Financial held 29,744 shares of Oncolytics Biotech worth $25.2K as of Q1 2026.
  • Vantage Point Financial left its Oncolytics Biotech share count unchanged in Q1 2026.
  • Oncolytics Biotech made up 0.01% of Vantage Point Financial's portfolio in Q1 2026, its #176 holding.
  • Vantage Point Financial first reported a position in Oncolytics Biotech in Q4 2024 and has held it in 6 quarters since.
  • Vantage Point Financial's Oncolytics Biotech position peaked at $41.6K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Vantage Point Financial's 13F filing for Q1 2026, filed 4 May 2026.